MedTrace Logo

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

NCT04388215 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-05-14

No results posted yet for this study

Summary

to evaluate the efficacy and safety of CKD-828, D326, and D337 combination therapy in Hypertensive patients with Dyslipidemia

Conditions

Interventions

DRUG

CKD-828

orally, 1 tablet once a day for 8 weeks

DRUG

CKD-828(placebo)

orally, 1 tablet once a day for 8 weeks

DRUG

D326

orally, 1 tablet once a day for 8 weeks

DRUG

D326(placebo)

orally, 1 tablet once a day for 8 weeks

DRUG

D337

orally, 1 tablet once a day for 8 weeks

DRUG

D337(placebo)

orally, 1 tablet once a day for 8 weeks

DRUG

D013

orally, 1 tablet once a day for 8 weeks

DRUG

D013(placebo)

orally, 1 tablet once a day for 8 weeks

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-23
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04388215 on ClinicalTrials.gov